HomeCompareETTX vs YUM

ETTX vs YUM: Dividend Comparison 2026

ETTX yields 91.32% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ETTX wins by $2.61M in total portfolio value
10 years
ETTX
ETTX
● Live price
91.32%
Share price
$2.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.71M
Annual income
$860,660.59
Full ETTX calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — ETTX vs YUM

📍 ETTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETTXYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETTX + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ETTX pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETTX
Annual income on $10K today (after 15% tax)
$7,762.56/yr
After 10yr DRIP, annual income (after tax)
$731,561.50/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, ETTX beats the other by $697,597.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETTX + YUM for your $10,000?

ETTX: 50%YUM: 50%
100% YUM50/50100% ETTX
Portfolio after 10yr
$1.41M
Annual income
$450,308.96/yr
Blended yield
31.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

ETTX
No analyst data
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETTX buys
0
YUM buys
0
No recent congressional trades found for ETTX or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETTXYUM
Forward yield91.32%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$2.71M$107.0K
Annual income after 10y$860,660.59$39,957.33
Total dividends collected$2.40M$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: ETTX vs YUM ($10,000, DRIP)

YearETTX PortfolioETTX Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$19,832$9,132.42$10,980$280.44+$8.9KETTX
2$38,148$16,926.92$12,185$435.72+$26.0KETTX
3$71,247$30,428.85$13,722$684.14+$57.5KETTX
4$129,347$53,112.88$15,773$1,090.14+$113.6KETTX
5$228,518$90,117.05$18,650$1,773.02+$209.9KETTX
6$393,309$148,794.86$22,921$2,966.37+$370.4KETTX
7$660,182$239,341.26$29,685$5,158.69+$630.5KETTX
8$1,081,855$375,459.71$41,216$9,453.02+$1.04METTX
9$1,732,607$575,022.24$62,672$18,571.31+$1.67METTX
10$2,714,550$860,660.59$107,016$39,957.33+$2.61METTX

ETTX vs YUM: Complete Analysis 2026

ETTXStock

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Full ETTX Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this ETTX vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETTX vs SCHDETTX vs JEPIETTX vs OETTX vs KOETTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.